Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial
Jiangsu Provincial Center for Disease Control and Prevention · Hubei Provincial Center for Disease Control and Prevention · +6 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,291
total citations
- FWCI
- 203.32
- Percentile
- 100%
- References
- 23
Citations per year
Authors
31- FZFengcai Zhu
Jiangsu Provincial Center for Disease Control and Prevention
- XGXu-Hua Guan
Hubei Provincial Center for Disease Control and Prevention
- YLYu-Hua Li
National Institutes for Food and Drug Control
- JHJian-Ying Huang
Wuhan University, Zhongnan Hospital of Wuhan University
- TJTao Jiang
Institute of Microbiology
Topics & keywords
Topics
Keywords
- Medicine
- Placebo
- Immunogenicity
- Clinical endpoint
- Adverse effect
- Randomized controlled trial
- Internal medicine
- Incidence (geometry)
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.